| Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | ||
|---|---|---|---|---|---|---|
Cash flows from operating activities: | ||||||
Net loss | ||||||
-125,533 | -128,711 | -131,396 | -87,906 | -50,655 | ||
Adjustments to reconcile net loss to net cash used in operating activities: | ||||||
Depreciation and amortization | ||||||
3,817 | 3,269 | 3,673 | 2,026 | 888 | ||
Stock-based compensation expense | ||||||
9,885 | 11,011 | 14,591 | 19,511 | 15,527 | ||
Change in fair value of contingent consideration | ||||||
- | - | - | 53 | 491 | ||
Loss on derivative liability | ||||||
- | - | -15,411 | -533 | - | ||
Amortization of debt discount | ||||||
1,026 | 514 | 3,349 | 889 | - | ||
Deferred rent expense | ||||||
- | 262 | 856 | -649 | - | ||
Loss on disposal of assets and impairment charges | ||||||
-232 | -236 | -80 | -1,034 | -31 | ||
Research and development license fees settled with convertible bond and stock | ||||||
- | 31,545 | 13,250 | - | - | ||
Interest incurred on converted bonds | ||||||
- | - | 2,759 | - | - | ||
Deferred income taxes | ||||||
486 | -365 | -327 | -491 | -270 | ||
Changes in operating assets and liabilities: | ||||||
Receivables, net | ||||||
3,738 | 4,483 | 5,691 | -1,055 | -1,081 | ||
Prepaid expenses and other assets | ||||||
-864 | 13,966 | 4,537 | 359 | 1,394 | ||
Inventories | ||||||
3,844 | 12,226 | 12,321 | 984 | -786 | ||
Accounts payable and accrued expenses | ||||||
19,345 | 3,527 | 18,791 | 16,120 | -241 | ||
Net cash used in operating activities | ||||||
-97,460 | -109,387 | -81,512 | -47,870 | -33,756 | ||
Proceeds from sale of property and equipment | ||||||
- | - | - | 335 | - | ||
Purchase of property and equipment | ||||||
13,572 | 3,321 | 5,440 | 1,487 | 3,310 | ||
Receipts of refundable deposit | ||||||
- | - | -110 | -1,000 | 1,000 | ||
Payments for licenses | ||||||
4,175 | 110 | 1,550 | -2,700 | 50 | ||
Acquisition of Polymed, net of cash acquired | ||||||
- | - | - | - | 11,076 | ||
Acquisition activity | ||||||
853 | - | - | - | 1,699 | ||
Purchases of short-term investments | ||||||
74,697 | 113,259 | 55,282 | 9,750 | 15,787 | ||
Sale of short-term investments | ||||||
99,090 | 67,727 | 52,144 | 15,261 | 12,615 | ||
Net cash (used in) provided by investing activities | ||||||
7,499 | -48,963 | -10,018 | 2,659 | -16,909 | ||
Cash flows from financing activities: | ||||||
Proceeds from sale of stock | ||||||
161,080 | 123,134 | 75,900 | 8,500 | 78,768 | ||
Proceeds from issuance of convertible bonds | ||||||
- | - | 30,000 | 38,000 | - | ||
Proceeds from issuance of debt | ||||||
6,464 | 50,000 | - | - | - | ||
Costs incurred related to the sale of stock | ||||||
1,103 | 5,518 | 10,168 | 1,537 | 1,013 | ||
Costs incurred related to the issuance of debt | ||||||
- | 1,993 | - | - | - | ||
Proceeds from exercise of stock options | ||||||
1,983 | 3,956 | 2,278 | 50 | 61 | ||
Investment from non-controlling interest | ||||||
- | - | 49 | 569 | 539 | ||
Repayment of finance lease obligations and long-term debt | ||||||
972 | 544 | 1,163 | 1,265 | 724 | ||
Repurchase of options and warrants | ||||||
- | - | - | - | 79 | ||
Payment of contingent consideration | ||||||
- | - | - | 3,184 | - | ||
Purchase of treasury stock | ||||||
- | - | - | 5,861 | 1,250 | ||
Net cash provided by financing activities | ||||||
167,452 | 169,035 | 96,896 | 35,272 | 76,302 | ||
Net (decrease) increase in cash and cash equivalents | ||||||
77,491 | 10,685 | 5,366 | -9,939 | 25,637 | ||
Effect of exchange rate changes on cash and cash equivalents | ||||||
389 | -175 | 793 | -431 | 337 | ||
Supplemental cash flow disclosures | ||||||
Interest paid | ||||||
4,925 | 2,977 | 109 | 144 | 92 | ||
Income taxes paid | ||||||
448 | 464 | 244 | 329 | 146 | ||
Non-cash investing and financing activities: | ||||||
Accrued purchases of property and equipment | ||||||
483 | 340 | 156 | 348 | 239 | ||
Common stock issued upon the conversion of bonds and derivative liability | ||||||
- | - | 98,929 | - | - | ||
Property and equipment financed under capital and finance leases | ||||||
- | - | 688 | - | - | ||
Accrued purchases of licenses | ||||||
- | 4,175 | - | 343 | - | ||
Cost of equity raise in accounts payable and accrued expenses | ||||||
- | - | 188 | 264 | - | ||
Convertible bond issued in lieu of licensing cash payment | ||||||
- | - | 7,000 | - | - | ||
Common stock issued in lieu of licensing cash payment | ||||||
- | 31,545 | 6,250 | - | - | ||
Equity consideration in connection with acquisition | ||||||
748 | - | - | - | - | ||
Notes payable assumed in connection with the acquisition of Polymed | ||||||
- | - | - | - | 3,275 | ||
Mortgage assumed in connection with the acquisition of CDE | ||||||
- | - | - | - | 1,099 | ||
Note receivable for restricted stock granted to officers | ||||||
- | - | - | - | 6,600 | ||
Polymed | ||||||
Stock issued in connection with acquisition | ||||||
- | - | - | 2,500 | - | ||